Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.
Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Episodes
125 total · newest first
Press play on any episode and the show keeps running from there.
Turning CAR T on and off, Fujifilm’s $2 billion investment, Affinivax raises $226 million, and startups to watchSponsorshttps://www.thescopemethod.com Story References10.1126/scitranslmed.abb6295https://affinivax.com/affinivax-announces-226…
AstraZeneca and W.H.O., vaccine I-told-you-so’s, Phitonex acquired by ThermoFisher, and Axsome reports success in migraine relief. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://www.rttnews.com/3157074/astrazeneca-s-covid-19-…
Trends in science from investors and immune-oncology to decentralized trials and basic research, we look back on 2020Sponsorshttps://www.thescopemethod.comStory Referenceswww.thenichepod.comMusic by Luke Goodsonhttps://www.soundcloud.com/lu…
Vaccines are here, capitalizing on capital with IPOs, and Gilead targets Hepatitis D. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issu…
Everlywell expands at-home testing, Bayer and Atara strike deal, and Moderna heads to the FDA. Sponsorshttps://www.thescopemethod.comStory Referenceshttps://www.prnewswire.com/news-releases/everlywell-announces-175-million-financing-to-expa…
This week, we take a thanksgiving break from the news cycle to bring you a special interview with a COVID survivor and healthcare worker, Trenton Barrick. He shares an inside perspective on the healthcare industry as well as his personal ex…
Pfizer submits to the FDA, how mRNA vaccines work, and Novartis drops a billion, but really only $50 million Story Referenceshttps://www.biospace.com/article/pfizer-and-biontech-to-submit-covid-19-vaccine-to-fda-for-emergency-use-today/http…
COVID19 vaccine news, an app to stop nightmares, Agios targets Sickle Cell disease, and Silverback files to go public. Sponsorshttps://www.thescopemethod.com Story Referenceshttps://www.pfizer.com/news/press-release/press-release-detail/pfi…
Aducanumab skeptics, Novo Nordisk and Merck make acquisitions, but first a market update.Sponsorshttps://www.thescopemethod.com Story References https://www.sciencemag.org/news/2020/11/biogen-s-alzheimer-s-drug-candidate-takes-beating-fda-a…
Syneos Health acquires Synteract, Apellis strikes a billion-dollar deal, and clinical trial patient enrollment, but first a market update.Sponsorshttps://www.thescopemethod.com Story Referenceshttps://www.investor.syneoshealth.com/news-rele…
This week, siteless with vision, IQVIA back on track, 36%, convalescent plasma, and Remdesivir approved. Sponsors https://www.thescopemethod.com Story References https://www.businesswire.com/news/home/20201020005645/en/LabCorp-Transforms-th…
Failures in sickle-cell therapy, CRO mergers in Asia, Praxis IPO, and wasp venom.Sponsors https://www.thescopemethod.com Story References https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-phase-2-strong-scd-stu…
Nobel prizes, clinical trials for tinnitus, Takeda’s billion-dollar deal, and the White House keeps science politicalSponsorshttps://www.thescopemethod.com Story Referenceshttps://www.nobelprize.org/prizes/chemistry/2020/summary/https://stm…
Another Alzheimer’s failure, COVID19 updates, two stories in the supplements space, and Taysha goes public. Sponsors https://www.thescopemethod.com Story References https://ir.acimmune.com/news-releases/news-release-details/ac-immune-report…
Finch does probiotics the expensive way, lipid nanoparticles, a followup on transparency, and LAVA gains immuno-therapy support.Sponsorshttps://www.thescopemethod.com Story Referenceshttps://www.businesswire.com/news/home/20200916005915/en/…
This week, vaccines and shark statistics, are noses the ultimate pipedream, and eye drops to replace eye-glasses. Sponsors https://www.thescopemethod.com Story References https://www.astrazeneca.com/content/astraz/media-centre/press-release…
Roche earns FDA approval for a combined flu/COVID diagnostic, I-Mab signs with Abbvie for $2 billion, PPD partners to treat lupus, and BioNTech/Pfizer add more COVID candidates while Moderna adds bad press.Sponsorswww.thescopemethod.com Sto…
This week, we take a break from our normal news cycle to focus on one big idea; healthcare is politics. But first, a quick update.Sponsorswww.thescopemethod.com Story Referenceshttps://www.sec.gov/Archives/edgar/data/1620463/000156459020041…
Johnson & Johnson acquires Momenta, the White House and FDA disagree, and the emergence of decentralized clinical trial management.Sponsorswww.thescopemethod.comStory Referenceshttps://www.momentapharma.com/investors-and-news/press-rele…
Samsung Biologics builds big, Modern (again), microparticles for timed-release chemotherapy, and Qiagen says ‘no’ to acquisitions.Sponsorswww.thescopemethod.com Story Referenceshttps://samsungbiologics.com/front/en/mediaCenter/pressReleases…
Biogen and Denali partner for Parkinson’s, the US pushes American-based drug manufacturing, and the secret to Parasitic Sexual Partners uncovered.Sponsorswww.thescopemethod.com Story Referenceshttps://investors.biogen.com/news-releases/news…
We review a few of the big winners from operation warp speed, Merck continues to be quietly successful, and a new CAR T treatment, Tecartus, gets FDA approval. Sponsorswww.thescopemethod.com Story Referenceshttps://s21.q4cdn.com/488056881/f…
